Complementemia in pregnancies with antiphospholipid syndrome.

Area of Science:

• Obstetrics and Gynecology
• Immunology
• Rheumatology

Background:

• Antiphospholipid syndrome (APS) pregnancy outcomes have improved with low molecular weight heparin and aspirin.
• Despite treatment, 10-15% of APS patients experience pregnancy losses, indicating incomplete understanding of pathogenesis.
• Thrombosis is the primary suspected mechanism, but it doesn't fully explain all pregnancy failures.

Discussion:

• Emerging evidence suggests the complement pathway plays a significant role in APS pregnancy complications.
• The precise mechanisms by which complement activation leads to pregnancy failure in APS are still under investigation.
• Low levels of complement components C3 and C4 (hypocomplementemia) are consistently associated with adverse pregnancy outcomes in APS.

Key Insights:

• Hypocomplementemia may serve as an early predictor of poor pregnancy outcomes in women with APS.
• Identifying hypocomplementemia early could allow for timely adjustments to conventional therapy.
• This finding highlights the complement system's potential as a therapeutic target in APS management.

Outlook:

• Further research is needed to elucidate the exact role of complement in APS-related pregnancy morbidity.
• Understanding these mechanisms could lead to novel therapeutic strategies beyond current treatments.
• Investigating the impact of low complement levels may refine risk stratification and treatment protocols for APS pregnancies.